Pomerantz Law Firm Alerts Investors on Class Action Lawsuit Against Charming Medical Ltd.

Investor Alert: Class Action Lawsuit Filed Against Charming Medical Ltd.

On January 29, 2026, Pomerantz LLP announced a class action lawsuit against Charming Medical Ltd. (NASDAQ: MCTA), aimed at investors who have incurred losses attributed to the company's alleged fraudulent conduct. This legal action comes as an important notice for those who purchased Charming securities during the specified class period, as they may be eligible to join the lawsuit.

Overview of the Situation

The lawsuit claims that Charming Medical Ltd. and certain of its senior officers have engaged in activities that may constitute securities fraud and other illegal business practices. Potential investors are encouraged to reach out to Pomerantz LLP to discuss their experiences and seek counsel. The firm has provided contact details for their representative, Danielle Peyton, who can be reached at [email protected] or via phone at 646-581-9980.

To facilitate the process, interested parties should provide their mailing address, contact number, and the number of shares they have acquired when they reach out for assistance. The deadline to apply for Lead Plaintiff status in this class action lawsuit is set for February 17, 2026.

Stock Performance and SEC Actions

Charming Medical experienced a tumultuous period before the filing of the lawsuit. On November 11, 2025, the company’s share price reached notable heights, closing at $29.36 with a peak of $31.70 during intraday trading. The market capitalization was estimated at around $504 million, with approximately 17.18 million shares outstanding. However, trouble brewed when the U.S. Securities and Exchange Commission (SEC) halted trading of Charming Medical’s securities from November 12 to 25, 2025, following allegations of market manipulation linked to a false inflate-and-dump strategy that utilized social media platforms.

Reports indicated that scammers had influenced market interest in Charming shares, leading to a spike in the stock’s value based on misinformation rather than genuine market activity. This alleged misconduct catalyzed the SEC intervention, accentuating the importance of regulatory oversight in protecting investors.

The Role of Pomerantz LLP

Pomerantz LLP, recognized as a leading law firm in corporate, securities, and antitrust class litigation, has a longstanding history of advocating for investors’ rights. Founded by Abraham L. Pomerantz, often referred to as the father of class actions, the firm has fought for over 85 years to provide restitution for victims of corporate misconduct. Their commitment continues, evidenced by successful recoveries for class members amounting to millions of dollars.

In light of these developments, investors who feel they have been wronged are strongly urged to consider their legal options. Joining the class action not only has the potential for compensation but also serves as a collective response to alleged corporate wrongdoings.

For those interested in learning more about their legal rights and options in this matter, further information is available through Pomerantz LLP’s website at www.pomerantzlaw.com.

Conclusion

As the legal proceedings progress, investors concerned about their stakes in Charming Medical Ltd. should remain vigilant and informed. The developments surrounding this class action lawsuit highlight critical issues within the financial market, emphasizing the necessity for transparency and accountability among publicly traded companies. Those affected have a limited window to assert their claims and should act without delay to protect their financial interests.